If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPortmeirion Regulatory News (PMP)

Share Price Information for Portmeirion (PMP)

Share Price is delayed by 15 minutes
Get Live Data
53.50    0.00 (0.00%)
Bid:
53.00
Ask:
54.00
Spread: 1.00 (1.887%)
Market Cap: £27.26m
PMP Live PriceLast checked at - London Stock Exchange

Intraday Portmeirion Share Chart

Grant of Options

26 Apr 2022 13:49

RNS Number : 4061J
Portmeirion Group PLC
26 April 2022
Β 

26 April 2022

Β 

Β 

Portmeirion Group PLC

(the "Company")

Β 

Grant of Options

Β 

The Portmeirion 2012 Approved Share Option Plan and The Portmeirion 2012 Unapproved Share Option Plan (the "Option Plans") and The Portmeirion Group 2018 Deferred Incentive Share Option Plan (the "Deferred Plan")

Β 

As part of its long-term employee remuneration and retention incentives, the Company announces that, on 25 April 2022, the following transactions occurred for the persons discharging managerial responsibilities ("PDMRs") as shown below:

Β 

Β 

Β 

Option Plans number of options granted at an exercise price of 570 pence per Ordinary Share (A)

Deferred Plan number of options granted at an exercise price of Β£1.00 (B)

Company directors/officers:

Β 

Β 

Michael Raybould

Chief Executive

40,000

10,813

Jacqui Gale

Chief Commercial Officer

25,000

5,706

Michael Knapper

Group Operations Director

25,000

5,506

William Robedee

President of North America

25,000

7,051

David Sproston

Group Finance Director

25,000

4,279

Moira MacDonald

Group Company Secretary

11,000

-

Β 

Total:

151,000

33,355

Note:

(A) Grant of options under Option Plans.Β 

(B) Grant of new options under Deferred Plan against 2021 performance and incentive arrangements (further detail below).

The Company granted 151,000 options over Ordinary Shares to the PDMRs shown above and a further 144,500 options over Ordinary Shares to other senior managers pursuant to the Option Plans. The options are subject to the achievement of performance targets as determined by the Remuneration Committee, and as required under the Option Plans. The options granted on 25 April 2022 are normally only exercisable if the increase in the average of the Group's basic adjusted (for changes in accounting standards and exceptional items) earnings per share for each of the three years ending 31 December 2022, 31 December 2023 and 31 December 2024 is at least 20% higher than that for the year ended 31st December 2021. The calculation of basic adjusted earnings per share shall take account of the number of shares and effective tax rates at the date of grant.

In addition, the Company granted 33,355 options to Executive Directors shown above over Ordinary Shares pursuant to the Deferred Plan. In accordance with the rules of the Deferred Plan, the number of options granted is based on the gross incentive payment earned by the relevant Director in respect of the year ended 31 December 2021.

PDMR Shareholdings

Β 

The total number of Ordinary Shares over which each PDMR holds options and the total number of Ordinary Shares with voting rights held following this Admission is:

Β 

Β 

Total number of options

over Ordinary Shares

Total number

Β of Ordinary Shares with

voting rights

Ordinary Shares percentage of Company's Ordinary Shares with voting rights

Β 

Michael Raybould

145,171

5,548

0.04%

Jacqui Gale

70,706

-

-

Michael Knapper

84,121

5,576

0.04%

William Robedee

Β 77,051

-

-

David Sproston

Β 88,279

1,315

0.01%

Moira MacDonald

Β 31,000

2,693

0.02%

Β Β Β Β Β 

Β 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

Β 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

_____________________________________________

Β 

Notification and public disclosure of transactions by persons discharging managerial responsibilities / person closely associated with them.

Β 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Β 

Company directors/officers:

Michael Raybould

Chief Executive

Jacqui Gale

Chief Commercial Officer

Michael Knapper

Group Operations Director

William Robedee

President of North America

David Sproston

Group Finance Director

Moira MacDonald

Group Company Secretary

Β 

2.

Reason for the notification

a)

Position/status

See 1(a) above for all positions - all classified as PDMRs of the Company

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Portmeirion Group PLC

b)

LEI

2138003QC9J6TLZJHO70

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares of 5 pence each

b)

Identification code

GB0006957293

c)

Nature of the transactions

(A) Performance related, Grant of options under Option Plans. Exercise period 26 April 2025 - 24 April 2032.

(B) Grant of new options under The Portmeirion Group 2018 Deferred Incentive Share Option Plan (the "Deferred Plan").

d)

Price(s) and volume(s)

Β 

In respect of (A) Grant of options under Option Plans

Price at grant: Nil

Β 

Exercise Price: Β£5.70 pence per Ordinary Share

Β 

Volume(s)

Β 

Β 

Options over Ordinary Shares

Michael Raybould

40,000

Jacqui Gale

25,000

Michael Knapper

25,000

William Robedee

25,000

David Sproston

25,000

Moira MacDonald

11,000

In respect of (B) Grant of options under Deferred Plan

Price at grant: Nil

Exercise Price (per PDMR in respect of all options granted): Β£1

Β 

Options over Ordinary Shares

Michael Raybould

10,813

Jacqui Gale

5,706

Michael Knapper

5,506

William Robedee

7,051

David Sproston

4,279

Β 

e)

Aggregated information

- Aggregated volume

- Price

In respect of (A) Grant of options under Option Plans

Nil, grant of options only

In respect of (B) Grant of options under Deferred Plan

Nil, grant of options only

f)

Date of the transactions

Β 

In respect of (A) Grant of options under Option Plans - 25 April 2022

Β 

In respect of (B) Grant of options under Deferred Plan 25 April 2022

Β 

g)

Place of the transactions

In respect of (A) Grant of options under Option Plans - - Off-market

In respect of (B) Grant of options under Deferred Plan - Off-market

Β 

Name of authorised official of issuer responsible for making notification:

Β 

Moira MacDonald

Company Secretary to Portmeirion Group PLC

Β 

ENQUIRIES:

Β 

Portmeirion Group PLC:

Mike Raybould, Chief Executive

+44 (0) 1782 743 443

mraybould@portmeiriongroup.com

David Sproston, Group Finance Director

+44 (0) 1782 743 443

dsproston@portmeiriongroup.com

Β 

Β 

Β 

Hudson Sandler:

Dan de Belder

+44Β (0)Β 207Β 796Β 4133

ddebelder@hudsonsandler.com

Nick Moore

Β 

nmoore@hudsonsandler.com

Β 

Panmure Gordon

Β 

Β 

(Nominated Adviser and Broker):

Β 

Β 

+44 (0) 207 886 2500

Β 

Β 

Freddy Crossley

Rupert Dearden

Corporate Broking

Β 

Β 

Β 

Β 

Singer Capital Markets

(Joint Broker):

Β 

+44 (0) 207 496 3000

Β 

Peter Steel / Asha Chotai

Investment Banking

Β 

Rachel Hayes

Β 

Β 

Β Β Β Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHSEMFEMEESELL
Date   Source Headline
30th Jun 20262:42 pmRNSReceipt of $2.7m from US Tariff refund claim
29th Jun 20269:51 amRNSNotification of major holdings
29th Jun 20269:48 amRNSNotification of major holdings
29th Jun 20269:18 amRNSNotification of major holdings
29th Jun 20267:00 amRNSCompletion of Asset Based Lending Facility
29th Jun 20267:00 amRNS-RSenior commercial hires
26th Jun 202612:30 pmRNSHolding(s) in Company
26th Jun 202611:17 amRNSHolding(s) in Company
25th Jun 20269:59 amRNSNotification of Major Holdings
24th Jun 20265:37 pmRNSHolding(s) in Company
23rd Jun 20264:32 pmRNSPDMR Shareholdings
23rd Jun 202611:36 amRNSResult of General Meeting and Total Voting Rights
10th Jun 20267:00 amRNSResult of Retail Offer
4th Jun 20268:00 amRNSProposed Retail Offer
4th Jun 20267:00 amRNSResult of Placing and Notice of General Meeting
3rd Jun 20264:40 pmRNSProposed Placing to raise at least £15 million
2nd Jun 20261:02 pmRNSAGM Resolutions
27th May 20263:08 pmRNSExercise of Options and Total Voting Rights
21st May 20263:30 pmRNS-RStatement re Government support for UK ceramics
11th May 202610:00 amRNSConfirmation of Director Appointment
6th May 20267:01 amRNSPreliminary Results
6th May 20267:00 amRNSDirectorate change
20th Apr 202612:10 pmRNSHolding(s) in Company
27th Feb 202610:37 amRNSHolding(s) in Company
12th Feb 20263:48 pmRNSNotification of Major Holdings
12th Feb 20263:38 pmRNSNotification of Major Holdings
3rd Feb 20267:00 amRNSFY 2025 Trading Update
8th Jan 20261:03 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RSenior strategic hires
6th Oct 20251:37 pmRNSInvestor Presentation via Investor Meet Company
25th Sep 20257:00 amRNSInterim results for the six months to 30 June 2025
21st Jul 20257:00 amRNSH1 2025 TRADING UPDATE
3rd Jun 20257:00 amRNSExercise of Options, PDMR & Voting Rights
20th May 20252:24 pmRNSAGM Resolutions
11th Apr 20257:00 amRNSAnnual Report & Accounts and Notice of AGM
7th Apr 20257:00 amRNSDirector's Dealing
2nd Apr 202512:04 pmRNSDirector's Dealing
2nd Apr 20257:20 amRNSDirector's Dealing
1st Apr 202511:39 amRNSDirector's Dealing
31st Mar 20257:00 amRNSPreliminary Results
17th Mar 20257:00 amRNSNotice of Results and Investor Presentation
6th Mar 20255:14 pmRNSHolding(s) in Company
20th Jan 20257:00 amRNSAppointment of Non-Executive Chairman
20th Dec 202410:02 amRNSHolding(s) in Company
17th Dec 20247:00 amRNSHolding(s) in Company
13th Dec 20247:00 amRNSTrading Update
28th Oct 20243:07 pmRNSHolding(s) in Company
1st Oct 20247:00 amRNSAppointment to the Board
19th Sep 20247:00 amRNSInterim Results
10th Sep 20247:00 amRNSNotice of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.